SCHEMBL1749098

SCHEMBL1749098

COc1cc2c(-c3cc4cccnc4[nH]3)cn(C)c2cc1OCCN1CCC(O)CC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.70
SYK P43405 1/20 0.45
DRD2 P14416 3/20 0.42
DRD3 P35462 3/20 0.42
PDGFRB P09619 1/20 0.40
RIPK1 Q13546 2/20 0.39
JAK2 O60674 1/20 0.39
LCK P06239 1/20 0.39
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
CDK7 P50613 1/20 0.39
BTK Q06187 1/20 0.39
LRRK2 Q5S007 1/20 0.39
AURKB Q96GD4 1/20 0.39
CSF1R P07333 1/20 0.39
ATM Q13315 1/20 0.39
EGFR P00533 1/20 0.39
ERBB2 P04626 1/20 0.39
SRC P12931 4/20 0.38
CLK2 P49760 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1748771 0.90 IGF1R (0.75) IGF1RSYKDRD2DRD3RIPK1
SCHEMBL1748777 0.88 IGF1R (0.73) IGF1RSYKDRD2DRD3LCK
SCHEMBL1748786 0.85 IGF1R (0.83) IGF1RSYKPDGFRBRIPK1JAK2
SCHEMBL1749198 0.84 IGF1R (0.84) IGF1RSYKPDGFRBRIPK1JAK2
SCHEMBL1780899 0.84 IGF1R (1.00) IGF1RSYKPDGFRBRIPK1JAK2
SCHEMBL1748415 0.83 IGF1R (0.69) IGF1RSYKSRC
SCHEMBL1778539 0.81 IGF1R (0.90) IGF1RSYKPDGFRBRIPK1JAK2
SCHEMBL1748512 0.80 IGF1R (0.62) IGF1RSYKDRD2DRD3RIPK1
SCHEMBL1749103 0.80 IGF1R (0.80) IGF1RSYKDRD2DRD3PDGFRB
SCHEMBL1749213 0.80 IGF1R (0.54) IGF1RJAK2LCKGSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968566-B2 Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2011-06-28 US disclosed
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2009-09-17 US disclosed
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US disclosed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US disclosed
EP-1732546-A2 NOVEL PYRROLO (2,3-B)PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS Aventis Pharma S.A. (FR) 2006-12-20 EP disclosed
WO-2005095399-A2 NOVEL PYRROLO (2,3-B)PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885SYK 379/4885DRD2 2844/4885
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885SYK 379/4885DRD2 2844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.